Table 2 Number of patients treated with non-HCT cellular therapies in 2023 by indication, donor type, and cell source.
Number of patients | DLI | CAR-T | MSC | NK cells | Selected/Expanded T cells or CIK | Regulatory T cells (TREGS) | Genetically modified T cells | Dendritic cells | Expanded CD34+ cells | Genetically modified CD34+ cells | Other | Total excluding DLI | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | allo | auto | ||
GvHD | 326 | 5 | 3 | 25 | 1 | 1 | 11 | 5 | 366 | 11 | |||||||||||||
Graft enhancement | 46 | 4 | 1 | 1 | 8 | 3 | 144 | 46 | 206 | 47 | |||||||||||||
Autoimmune disease | 36 | 31 | 4 | 3 | 31 | 43 | |||||||||||||||||
Genetic disease | 4 | 12 | 5 | 9 | 12 | ||||||||||||||||||
Infection | 1 | 3 | 108 | 7 | 2 | 16 | 1 | 10 | 141 | 7 | |||||||||||||
Malignancy—ALL | 47 | 519 | 2 | 15 | 11 | 4 | 3 | 1 | 9 | 86 | 525 | ||||||||||||
Malignancy—HL/NHL | 25 | 3437 | 12 | 20 | 1 | 5 | 1 | 11 | 58 | 3454 | |||||||||||||
Malignancy—Myeloma | 0 | 736 | 25 | 2 | 11 | 25 | 749 | ||||||||||||||||
Malignancy - other indication | 12 | 76 | 11 | 8 | 8 | 1 | 14 | 8 | 5 | 14 | 13 | 2 | 4 | 42 | 54 | 102 | 170 | ||||||
DLI for graft enhancement/failure | 686 | ||||||||||||||||||||||
DLI for residual disease | 432 | ||||||||||||||||||||||
DLI for relapse | 1299 | ||||||||||||||||||||||
DLI per protocol | 458 | ||||||||||||||||||||||
Total | 2875 | 84 | 4804 | 415 | 19 | 63 | 3 | 164 | 20 | 28 | 11 | 16 | 14 | 16 | 0 | 12 | 1 | 4 | 16 | 222 | 130 | 1024 | 5018 |
